PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30901302-10	2019	In patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS (HR, 0.579), PFS (HR, 0.556), and OS (HR, 0.330) and slightly increased serious adverse events (35.7% v 28.6%), but the proportion of patients receiving at least six cycles of R-CHOP was similar between treatment arms (92.9% v 93.0%).	ibrutinib	39-48	DNA damage inducible transcript 3	Homo sapiens	252-256	
30901302-11	2019	In patients age 60 years or older, ibrutinib plus R-CHOP worsened EFS, PFS, and OS, increased serious adverse events (63.4% v 38.2%), and decreased the proportion of patients receiving at least six cycles of R-CHOP (73.7% v 88.8%).	ibrutinib	35-44	DNA damage inducible transcript 3	Homo sapiens	210-214	
30901302-14	2019	In patients age 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes.	ibrutinib	35-44	DNA damage inducible transcript 3	Homo sapiens	122-126	
29724297-5	2018	Further study showed that ibrutinib treatment increased ERS-related protein expression, including Bip, ATF4 and CHOP, suggesting the induction of ER-stress in Reh cells.	ibrutinib	26-35	DNA damage inducible transcript 3	Homo sapiens	112-116	
24625454-10	2014	CONCLUSIONS: The future for new treatment options in DLBCL is promising with current clinical trials testing novel targeted agents such as bortezomib, lenalidomide, and ibrutinib as the "X" in R(X)CHOP.	ibrutinib	169-178	DNA damage inducible transcript 3	Homo sapiens	197-201	
25042202-0	2014	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.	ibrutinib	15-24	DNA damage inducible transcript 3	Homo sapiens	103-107	
25042202-21	2014	INTERPRETATION: Ibrutinib is well tolerated when added to R-CHOP, and could improve responses in patients with B-cell non-Hodgkin lymphoma, but our findings need confirmation in a phase 3 trial.	ibrutinib	16-25	DNA damage inducible transcript 3	Homo sapiens	60-64	
34739844-4	2021	The 3-year event-free survival of younger patients (age <=60 years) treated with ibrutinib plus R-CHOP was 100% in the MCD and N1 subtypes while the survival of patients with these subtypes treated with R-CHOP alone was significantly inferior (42.9% and 50%, respectively).	ibrutinib	81-90	DNA damage inducible transcript 3	Homo sapiens	205-209